Human Genome Sciences (HGS) starts at the molecular level for good health. Using its expertise in human genetics, the biopharmaceutical discovery and development firm is working on therapies for infectious and autoimmune diseases, cardiovascular disease, and cancer. In 2011 lead candidate Benlysta gained FDA approval to treat systemic lupus and has since been extended into international markets. The company's only other commercial product is raxibacumab, an antibody treatment for inhaled anthrax. In addition, the company provides contract research and manufacturing services to other biotechs. Benlysta was developed through a partnership with GlaxoSmithKline (GSK). In 2012 HGS was acquired by GSK.